Louis J. DeGennaro, Ph.D.
Interim President and CEO
Louis J. DeGennaro, Ph.D., was named interim president and CEO of The Leukemia & Lymphoma Society (LLS) in February 2014. DeGennaro has been a critical member of the LLS executive leadership team since he joined LLS in 2005.
As a member of the leadership team, DeGennaro helped steward LLS operations. He was named LLS chief mission officer in 2009, with responsibility for leadership of LLS's mission functions of research, patient access, education, public policy and advocacy. He continues to serve as chief mission officer with his role as interim president and CEO.
DeGennaro is recognized as a key architect of LLS's cures and access agenda to help save lives of blood cancer patients and the LLS Therapy Acceleration Program® - a venture philanthropy endeavor that demonstrates the role of nonprofit organizations in supporting drug discovery and development with the biotechnology industry.
DeGennaro received his Ph.D. in biochemistry from the University of California at San Francisco and did his postdoctoral research at Yale University School of Medicine. His previous academic appointments include research group leader at Max Planck Institute in Munich, Germany, and associate professor of neurology and cell biology at the University of Massachusetts Medical School.
DeGennaro has more than 25 years of research and executive management experience. His private-sector positions include senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, NJ, and executive vice president for research and development, SynX Pharma, Inc., Toronto, Canada.